ClinicalTrials.gg
Not yet recruitingNCT07509684Updated Apr 13, 2026

A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of ALK-N001 for Injection in Advanced Solid Tumors, sponsored by Zhejiang Anglikang Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Zhejiang Anglikang Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
190
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a multicenter, open-label, dose-escalation and cohort-expansion Phase Ib/II clinical trial conducted in patients with advanced solid tumors, aiming to evaluate the safety, pharmacokinetics and efficacy of ALK-N001 for injection as monotherapy in the treatment of advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • AlK-N001
  • Advanced Solid Tumors
  • Phase Ib/II
03

In context

Lead sponsor

Zhejiang Anglikang Pharmaceutical Co., Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Voluntarily signs the form, understands the study, and is willing and able to comply with all study procedures.
  • 2. Male or female aged 18 years or older.
  • 3. Has and/or cytologically confirmed unresectable and/or advanced solid tumor.
  • 4. Dose Expansion Phase (Phase Ib): Patients with advanced solid tumors who have failed standard treatment, currently have no standard treatment available, or are intolerant to standard treatment, including but not limited to lung cancer, pancreatic cancer, esophageal cancer, liver cancer, breast cancer (triple-negative breast cancer or low/ultra-low expression breast cancer), ovarian cancer, cervical cancer, and other tumor types.
  • 5.Dose Expansion Phase (Phase II): Including but not limited to the following 4 cohorts: ① Lung Cancer Cohort (small cell lung cancer, non-squamous non-small cell lung cancer, squamous cell lung cancer): Failed at least one line of standard treatment; ② Breast Cancer Cohort (triple-negative breast cancer or HER2 low/ultra-low expression breast cancer): Failed at least one line of standard treatment; ③ Ovarian Cancer, Cervical Cancer, Pancreatic Cancer, and Liver Cancer Cohort: Failed at least one line of standard treatment; ④ Esophageal Cancer Cohort: Failed at least one line of standard treatment. There is documentation confirming radiologically confirmed disease progression after the last anti-tumor treatment. If a specific tumor type shows clear anti-tumor activity signals (e.g., meeting the preset efficacy threshold) during the Phase Ib study, the sponsor may initiate an additional dose expansion cohort for the effective tumor type during or after the Phase II study, to further verify its efficacy and safety.
  • 6.According to Version 1.1, there is at least one measurable tumor lesion. (Tumor lesions located in previously irradiated areas or other locally treated sites are generally not considered measurable, unless there is clear evidence of progression of the lesion.)
  • 7. (ECOG) performance status of 0 or 1.
  • 8. Expected survival time of ≥ 3 months.
  • 9.Adequate organ function as follows: hematologic system (no blood transfusion or hematopoietic growth factor within 14 days): ≥1.5×10⁹/L, ≥90×10⁹/L, ≥90 g/L; liver function: total ≤1.5×, ≤3×ULN (≤5×ULN in patients with liver metastasis or liver cancer), aspartate aminotransferase ≤3×ULN (≤5×ULN in patients with liver metastasis or liver cancer); renal function: creatinine ≤1.5×ULN, ≥50 mL/min calculated by Cockcroft-Gault formula (required only if creatinine >1.5×ULN); coagulation function: ≤1.5×ULN, international normalized ratio ≤1.5×ULN.
  • 10. Male subjects and females of must agree to use non-pharmacological measures from signing informed consent until 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  • 1. Have received anti-tumor therapies such as chemotherapy, radiotherapy (local bone radiotherapy within 2 weeks), biological therapy, macromolecular targeted therapy, immunotherapy, or TIL cell therapy within 4 weeks prior to the first dose of the study drug, including the following: Have received anti-cancer endocrine therapy (excluding GnRH agonists or inhibitors, endocrine replacement therapy or ), oral fluoropyrimidines, small-molecule targeted drugs as well as traditional Chinese medicines with anti-tumor indications within 2 weeks or 5 half-lives prior to the first dose of the study drug (whichever is longer); Have received CAR-T, CAR-NK cell therapy or tumor vaccine therapy within 3 months prior to the use of the study drug; Have received inactivated viral vaccine injection within 2 weeks prior to the use of the study drug, or non-inactivated viral vaccine injection within 4 weeks prior to the use of the study drug; Have received other unlisted clinical trial drugs within 4 weeks or 5 half-lives prior to the use of the study drug (whichever is shorter);
  • 2. Have used strong inducers or strong inhibitors within 7 days prior to the first dose or need to use them during the study;
  • 3. Have previously used DXD analogues, irinotecan and other drugs;
  • 4. Have a known history of severe allergic reactions ( v6.0 grade ≥3) to the components of the preparations used in the trial;
  • 5. Have central nervous system (CNS) and/or ; Study participants with treated are allowed to participate in this study if the brain metastatic lesions have been stable for at least 1 month, there is no evidence of new or enlarged brain metastases, and therapy has been discontinued for 2 weeks before the first dose;
  • 6. Have other malignant tumors within 5 years before enrollment; Exceptions include cured carcinoma in situ of cervix, cutaneous squamous cell carcinoma, basal cell carcinoma or papillary thyroid carcinoma;
  • 7. Have clinically uncontrolled third-space effusions that are deemed unsuitable for enrollment by the investigator;
  • 8. Have pre-existing severe digestive diseases such as chronic inflammatory bowel disease and/or intestinal obstruction or chronic diarrhea;
  • 9. Have severe cardiovascular diseases, including but not limited to: a) Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, second to third-degree atrioventricular block, etc.; b) Acute coronary syndrome, congestive heart failure, stroke or other grade 3 and above cardiovascular events within 6 months before the first dose; c) (NYHA) functional classification ≥ grade II or (LVEF) \<50%, or other structural heart diseases judged to be high-risk by the investigator; d) examination showing >450ms (male), >470ms (female) (according to Fridericia formula: QTcF=QT/(RR\^0.33)), (Note: If the initial examination is abnormal, re-measure twice within 48 hours and take the average of three measurements to judge eligibility); e) Clinically uncontrolled hypertension (systolic blood pressure ≥150mmHg and/or diastolic blood pressure ≥100mmHg after intervention); f) Poorly controlled diabetic patients defined as (HbA1c) ≥8.0%;
  • 10. Currently have active infections and have received systemic anti-infective treatment within 2 weeks before the first dose (excluding and prophylactic use for urinary tract surgery);
  • 11. Have active during screening (HBsAg positive and HBV-DNA >500IU/ml or the lower limit of detection of the study center [only when the lower limit of detection of the study center is higher than 500IU/ml]), active (patients with positive HCV antibodies but HCV-RNA \< the lower limit of detection of the study center are allowed to be enrolled); Patients receiving preventive antiviral treatment other than interferon are allowed to be enrolled; Patients with positive screening results for active syphilis or (HIV);
  • 12. Have severe pulmonary diseases such as pulmonary embolism and interstitial lung disease within 6 months before the first dose;
  • 13. Have a history of deep vein thrombosis or any other severe thromboembolism within 6 months before the first dose (implantable venous access port or catheter-related thrombosis, superficial venous thrombosis or lacunar infarction are not regarded as "severe" thromboembolism); Known familial and/or acquired thrombophilia, such as hereditary or acquired defects in anticoagulant proteins, coagulation factors, fibrinolytic proteins, or high thromboembolic risk due to acquired risk factors;
  • 14. Have active hemorrhagic diseases or other grade ≥3 hemorrhage history within 4 weeks before the first dose; High bleeding risk caused by obvious invasion of large arteries by tumor metastases;
  • 15. Toxic reactions from previous anti-tumor treatments have not recovered to ≤ grade 1 (severity assessed according to NCI-CTCAE v6.0, excluding alopecia and other toxicities judged to have no safety risks by the investigator) or the level specified in the inclusion criteria;
  • 16. Currently receiving thrombolytic or anticoagulant therapy (excluding prophylactic anticoagulant therapy);
  • 17. Have received hematopoietic stem cell transplantation or organ transplantation;
  • 18. Have a history of mental disorders (including epilepsy or dementia, etc.);
  • 19. Study participants have a history of drug abuse, or have medical, psychological or social conditions that may interfere with study participation or evaluation of study results;
  • 20. Female study participants who are breastfeeding or have positive blood/urine pregnancy results during the screening period;
  • 21. Any other conditions of the study participant (such as psychological, geographical or medical conditions) that do not allow them to comply with the study and follow-up procedures, or other circumstances where the study participant is deemed unsuitable for enrollment in this study by the investigator.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    ALK-N001 (37.5 mg/m²)

    Participants will receive ALK-N001 for Injection at a dose of 37.5 mg/m², administered by intravenous infusion over a fixed duration of 2 hours (allowable range: ±20 minutes), once every 2 weeks (Q2W). A treatment cycle is defined as 28 days.

    Drug: ALK-N001 for Injection

  • Experimental
    ALK-N001 (50 mg/m²)

    Participants will receive ALK-N001 for Injection at a dose of 50mg/m², administered by intravenous infusion over a fixed duration of 2 hours (allowable range: ±20 minutes), once every 2 weeks (Q2W). A treatment cycle is defined as 28 days.

    Drug: ALK-N001 for Injection

  • Experimental
    ALK-N001 (62.5 mg/m²)

    Participants will receive ALK-N001 for Injection at a dose of 62.5 mg/m², administered by intravenous infusion over a fixed duration of 2 hours (allowable range: ±20 minutes), once every 2 weeks (Q2W). A treatment cycle is defined as 28 days.

    Drug: ALK-N001 for Injection

Interventions

  • DrugALK-N001 for Injection

    The drug is administered via intravenous infusion at a constant rate over 2 hours ± 20 minutes. The primary dosing schedule was every 2 weeks (Q2W) in a 28-day cycle, while an every 3 weeks (Q3W) schedule with a 21-day cycle was also explored.

    Also known as: QHL-1618, ALK-N001

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    The proportion of evaluable participants achieving a best overall response of Complete Response (CR) or Partial Response (PR).

    Time frame: Through study completion, an average of 2 years.

Secondary outcomes

  1. Disease Control Rate (DCR)

    Proportion of evaluable participants with a best overall response of CR, PR, or Stable Disease (SD).

    Time frame: Through study completion, an average of 2 years.

  2. Duration of Response (DOR)

    Time from the date of first documented response (CR or PR) to the date of first documented disease progression or death due to any cause.

    Time frame: Through study completion, an average of 2 years.

  3. Progression-Free Survival (PFS)

    Time from the date of first dose to the date of first documented disease progression or death due to any cause.

    Time frame: Through study completion, an average of 2 years.

  4. Overall Survival (OS)

    Time from the date of first dose to the date of death due to any cause.

    Time frame: Through study completion, an average of 2 years.

  5. PFS Rate at 6, 12, and 24 Months

    The proportion of participants alive and free from disease progression at 6, 12, and 24 months after the first dose.

    Time frame: Through study completion, an average of 2 years.

  6. OS Rate at 12 and 24 Months

    The proportion of participants alive at 12 and 24 months after the first dose.

    Time frame: Through study completion, an average of 2 years.

  7. Incidence of Adverse Events (AEs)

    Frequency, severity (graded by NCI CTCAE v6.0), and relationship to study drug of alladverse events (AEs) .

    Time frame: Through study completion, an average of 2 years.

  8. Incidence of Serious Adverse Events (SAEs)

    Frequency, severity (graded by NCI CTCAE v6.0), and relationship to study drug of serious adverse events (SAEs).

    Time frame: Through study completion, an average of 2 years.

  9. Incidence of AEs Leading to Permanent Treatment Discontinuation

    Frequency of AEs that result in permanent discontinuation of the study drug.

    Time frame: Through study completion, an average of 2 years.

  10. Area Under the Curve (AUC) of ALK-N001

    Area under the plasma concentration-time curve for ALK-N001.

    Time frame: Through study completion, an average of 2 years.

  11. Maximum Concentration (Cmax) of ALK-N001

    Maximum observed plasma concentration of ALK-N001.

    Time frame: Through study completion, an average of 2 years.

  12. Trough Concentration (Ctrough) of ALK-N001

    Trough plasma concentration of ALK-N001.

    Time frame: Through study completion, an average of 2 years.

  13. Time to Maximum Concentration (Tmax) of ALK-N001

    Time to reach the maximum plasma concentration of ALK-N001.

    Time frame: Through study completion, an average of 2 years.

  14. Clearance (CL) of ALK-N001

    Systemic clearance of ALK-N001.

    Time frame: Through study completion, an average of 2 years.

  15. Volume of Distribution (Vd) of ALK-N001

    Volume of distribution of ALK-N001.

    Time frame: Through study completion, an average of 2 years.

Other outcomes

  1. Legumain Expression Level in Tumor Tissue

    Exploratory assessment of Legumain protein expression levels in archival or fresh tumor tissue samples and its potential correlation with clinical outcomes.

    Time frame: Through study completion, an average of 2 years.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Apr 3, 2026
StartEst.
Apr 2026
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2029
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07509684
Lead sponsor
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Apr 3, 2026
Start date
Apr 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Jun 2029 (estimated)
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion